Clinical Trials Logo

Filter by:
NCT ID: NCT05568225 Recruiting - Clinical trials for Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Start date: November 22, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

NCT ID: NCT05568160 Recruiting - Vasoplegic Syndrome Clinical Trials

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

NOVACC
Start date: January 2, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double blind, multicenter study following surgery with extracorporeal circulation to compare blood pressure optimization with vasopressin versus noradrenaline. It is planned to include 840 patients in order to have 420 patients with vasoplegic syndrome. The primary objective of this study is to determine whether the use of vasopressin to maintain blood pressure following cardiac surgery decreases the number of patients with acute renal failure and/or death compared with the usual use of norepinephrine. Participation in the study involves daily follow-up at D1, D2, and D7 of the onset of the syndrome and then follow-up at D30 and D90.

NCT ID: NCT05568095 Active, not recruiting - Clinical trials for Advanced Upper Gastrointestinal Tract Adenocarcinoma

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

STAR-221
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

NCT ID: NCT05567978 Recruiting - Clinical trials for Pupillometry Index in Brain Lesion

Comparison of 2 Pupillometric Indices in Cerebral Brain Patients

LYNX
Start date: October 31, 2022
Phase:
Study type: Observational [Patient Registry]

Pupillary examination, and in particular pupillary reactivity to light, is fundamental to the monitoring and follow-up in intensive care units of patients with acute brain injury. A pupillometric index combining different parameters of pupillary light reflex has been described as predictive of intracranial hypertension and the neurological outcome of the patient.

NCT ID: NCT05567874 Completed - Clinical trials for SARS CoV 2 Infection

Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

COVIDIN
Start date: January 3, 2022
Phase:
Study type: Observational

The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement. The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.

NCT ID: NCT05567796 Active, not recruiting - Obesity Clinical Trials

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

REDEFINE 1
Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

NCT ID: NCT05567692 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Subjects With T2D or at Risk of T2D Cohort Follow-up

DESCENDANCE
Start date: February 10, 2023
Phase:
Study type: Observational

The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model.

NCT ID: NCT05567419 Not yet recruiting - Clinical trials for SARS-CoV-2 Infection

SARS-CoV-2 in Stools Compared to Respiratory Viral Strains.

Spread-COVID
Start date: November 2022
Phase:
Study type: Observational

The aim of the study is to characterize and to quantify SARS-CoV-2 strains in stools, in comparison with the viral strains in respiratory samples, from patients hospitalized for COVID-19. The methods will be standard ddPCR quantifying SARS-CoV-2 RNA and next generation sequencing-whole genome sequencing. The expected results will allow us to better understand SARS-CoV-2 dynamics and compartmentalization, both in the respiratory tract and in digestive-related tissues, according to the evolution of SARS-CoV-2 variants.

NCT ID: NCT05567328 Recruiting - Liver Diseases Clinical Trials

Validation of the New Vibration-guided FibroScan Examination

Start date: October 26, 2022
Phase: N/A
Study type: Interventional

This is an European, prospective, interventional, multicenter clinical investigation that will take place in 2 French sites. 100 adults patients will be included. The study objective is to compare the applicability between the Research FibroScan and the reference FibroScan examination performed on the liver.

NCT ID: NCT05567315 Completed - Oocyte Retrieval Clinical Trials

Interest of Hypnosis in Virtual Reality on Nociception During Oocyte Retrieval in a Medically Assisted Reproduction Procedure

HypnoPO
Start date: October 11, 2022
Phase: N/A
Study type: Interventional

Study on the effect of the virtual hypnosis mask in addition to local anaesthesia on anxiety and perioperative pain during oocyte puncture